KM Research Hub
← 返回论文库
已完成 入排:待复核 图源:可得 入排置信度 0.45

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E Cortes, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Koji Sasaki, Carla Boquimpani, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea

Blood Adv 9(16) 4248-4259

PMID40334072
PMCIDPMC12391778
DOI10.1182/bloodadvances.2025016042
发表日期2025-05-07
入排依据:The study is an oncology, human, randomized, Phase III trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is major molecular response (MMR) at week 156, a categorical response rate, not a time-to-event outcome. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort.
摘要

摘要

The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are efficacious and maximize tolerability. The 24- and 96-week analyses from ASCEMBL demonstrated superior efficacy, safety, and tolerability of asciminib when compared with bosutinib in later-line therapy, thereby meeting the primary and key secondary objectives. With nearly 4 years of follow-up, data from ASCEMBL continued to demonstrate the superior efficacy, safety, and tolerability of asciminib over bosutinib. At week 156, the major molecular response (MMR) rates remained higher with asciminib (33.8%) than with bosutinib (10.5%); the difference in MMR rates between arms, after adjusting for baseline major cytogenetic response, was 23.2% (95% confidence interval, 13.14-33.18; 2-sided P < .001). Asciminib continued to cause fewer grade ≥3 adverse events (AEs; 59.6% vs 68.4%) and fewer AEs that led to treatment discontinuation (8.3% vs 27.6%) than bosutinib. This updated analysis also includes patients who switched to asciminib because of a lack of efficacy with bosutinib. Two of the 25 patients who switched achieved MMR by the end of study, suggesting that earlier incorporation of asciminib, before other TKIs, may improve responses, albeit modestly. These long-term results further solidify asciminib as the therapy of choice for patients with CML-CP who were previously treated with ≥2 previous TKIs. This trial was registered at clinicaltrials.gov as #NCT03106779.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 3

Figure 3. Cumulative incidences of molecular responses. Cumulative incidence of MMR (A) and BCR :: ABL1 IS ≤1% (B). ∗Nonresponders were censored at their last molecular assessment date. †Discontinuation from treatment for any reason without previous achievement of MMR was considered a competing event. ‡Based on 142 of 157 patients (90.4%) who received asciminib and 72 of 76 (94.7%) who received bosutinib with BCR :: ABL1 IS >1% at baseline. §Discontinuation from treatment for any reason without previous achievement of BCR :: ABL1 IS ≤1% was considered a competing event. ||The probability of BCR :: ABL1 IS ≤1% was not estimable from week 104 onward because no patients were eligible to achieve BCR :: ABL1 IS ≤1%. NE, not estimable.

A

MMR

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

BCR::ABL1IS≤1%

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:off origin start
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. MMR and BCR :: ABL1 IS ≤1% at week 156. MMR ( BCR :: ABL1 IS ≤0.1%). ∗Based on the full analysis set. In patients without MMR at week 156, the reasons were treatment failure (asciminib, n = 3; bosutinib, n = 5), missing assessments (asciminib, n = 3), and lost response (asciminib, n = 1). †The treatment difference, after adjusting for the baseline MCyR status, was 23.16% (95% CI, 13.14-33.18; 2-sided P < .001) at week 156. ‡Based on 142 of 157 patients (90.4%) who received asciminib and 72 of 76 (94.7%) who received bosutinib with BCR :: ABL1 IS >1% at baseline. §The treatment difference after adjusting for MCyR status at baseline was 32.34% (95% CI, 21.44-43.24; 2-sided P < .001) at week 156.
非 KM Figure
Figure 2Figure 2. MMR rate difference (95% CI) between treatment at week 156 from subgroup analyses. ∗Patients with T315I and V299L BCR :: ABL1 mutations or a nonevaluable mutation assessment were excluded from the subgroup analysis. CRF, case report form.
非 KM Figure
Figure 4Figure 4. All-grade AEs by time period with asciminib. ∗Includes thrombocytopenia and platelet count decreased. †Includes neutropenia and neutrophil count decreased. ‡Includes anemia, hemoglobin decreased, and macrocytic anemia. §A patient with multiple occurrences of an AE is counted only once in that time period. Percentages were rounded to the nearest whole number. The denominator for incidence is the number of patients who were ongoing at the beginning of each time period who have not yet experienced the event. The denominator for prevalence is the number of patients who were ongoing at the beginning of each time period. ALT, alanine aminotransferase; AST, aspartate aminotransferase.
非 KM Figure